Johnson & Johnson has completed the acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company, for $3.05 billion in cash. The acquisition adds Halda’s proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC™) platform to Johnson & Johnson’s portfolio, enabling the development of oral, targeted therapies for multiple solid tumors, including prostate cancer.
The deal brings HLD-0915, a clinical-stage therapy for prostate cancer, into Johnson & Johnson’s oncology pipeline. HLD-0915 is a once-daily oral therapy that employs the RIPTAC™ platform, providing a precision cancer cell-killing approach capable of overcoming treatment resistance. Alongside HLD-0915, the acquisition includes several earlier-stage candidates for breast, lung, and other tumor types, expanding Johnson & Johnson’s oncology offerings. The technology may also facilitate the creation of targeted therapies beyond oncology.
The acquisition strengthens Johnson & Johnson’s longstanding focus on innovation in prostate cancer and positions the company to advance novel therapies that address unmet patient needs.
The company will account for the acquisition as a business combination, with the transaction expected to result in a total dilution of approximately $0.20 to Adjusted Earnings Per Share, split equally between 2025 and 2026. This reflects non-recurring charges related to Halda employee equity awards, financing, and integration costs. Full-year 2026 guidance will be discussed during Johnson & Johnson’s fourth-quarter earnings call on January 21, 2026.
Johnson & Johnson, leveraging its expertise in Innovative Medicine and MedTech, continues to pursue solutions across the full spectrum of healthcare. The company aims to develop smarter, less invasive treatments and innovative therapies that prevent, treat, and cure complex diseases, with the acquisition of Halda Therapeutics representing a strategic step in expanding its next-generation oncology capabilities.
